Home › Companies › X4 PHARMACEUTICALS INC. › 2023-2024
At X4 PHARMACEUTICALS INC.'s shareholder meeting held June 10, 2024, in the 2023-2024 proxy season, 88 asset managers reported how they voted in their SEC Form N-PX filings, covering 525 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO HOLD A NON-BINDING, ADVISORY "SAY-ON-PAY" VOTE ON THE COMPANY'S EXECUTIVE COMPENSATION. — X4 PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: X4 PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and X4 PHARMACEUTICALS INC.’s Form 8-K, filed June 11, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 10, 2024: 5 items on X4 PHARMACEUTICALS INC.’s Form 8-K, filed June 11, 2024: 3 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore X4 PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are X4 PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: David McGirr, M.B.A. | 83,110,008 | -- | -- | 11,137,060 | 36,561,395 | 88% | Elected | — |
| Elect Director: Paula Ragan, Ph.D. | 93,318,699 | -- | -- | 928,369 | 36,561,395 | 99.0% | Elected | — |
| Elect Director: Michael S. Wzyga | 83,840,957 | -- | -- | 10,406,111 | 36,561,395 | 89% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 129,116,244 | 620,394 | 1,071,825 | -- | -- | 99.5% | Approved | — |
| 3. Non-Binding Advisory "Say-On-Pay" Vote on Named Executive Officer Compensation | 89,159,259 | 4,443,024 | 644,785 | -- | 36,561,395 | 95% | Approved | — |
Source: X4 PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 11, 2024 — read the filing on EDGAR.
Each item below shows how the 88 asset managers that disclosed a X4 PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of X4 PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: To elect three (3) nominees, David McGirr, Paula Ragan, Ph.D. and Michael Wyzga to the Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duty elected and qualified: David McGirr
X4 PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David McGirr, M.B.A.”): 83,110,008 for, 11,137,060 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified or until their earlier death, resignation of …”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 14,776,175 for, 371,113 withheld, 4,974 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,116,249 | 0 | 0 | 0 | For |
| BlackRock | 3,598,208 | 0 | 0 | 0 | For |
| Fidelity | 2,432,292 | 0 | 0 | 0 | For |
| TIAA | 354,661 | 0 | 0 | 0 | For |
| Charles Schwab | 323,843 | 0 | 0 | 0 | For |
| Equitable | 220,802 | 0 | 0 | 83,650 | Mixed |
| Royce | 244,494 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 227,245 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,700 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 61,735 | Withhold |
| State Street | 50,492 | 0 | 0 | 0 | For |
| Pacific Life | 44,764 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 42,078 | Withhold |
| Voya | 0 | 0 | 0 | 40,598 | Withhold |
| Bridge Builder Trust | 39,394 | 0 | 0 | 0 | For |
| Nationwide | 0 | 0 | 0 | 38,485 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 23,694 | Withhold |
| ProShares | 0 | 0 | 0 | 20,336 | Withhold |
| DWS | 0 | 0 | 0 | 18,973 | Withhold |
| Victory Capital | 0 | 0 | 0 | 15,953 | Withhold |
| Principal | 0 | 0 | 0 | 13,691 | Withhold |
| Calvert | 0 | 0 | 0 | 10,167 | Withhold |
| T. Rowe Price | 7,572 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 4,974 | 0 | Abstain |
| PENN SERIES FUNDS INC | 4,800 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% of fund votes cast · no official result
Description as filed by funds: To elect three (3) nominees, David McGirr, Paula Ragan, Ph.D. and Michael Wyzga to the Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duty elected and qualified: Michael Wyzga
The 30 asset managers below reported 14,901,903 for, 245,385 withheld, 4,974 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,116,249 | 0 | 0 | 0 | For |
| BlackRock | 3,598,208 | 0 | 0 | 0 | For |
| Fidelity | 2,432,292 | 0 | 0 | 0 | For |
| TIAA | 354,661 | 0 | 0 | 0 | For |
| Charles Schwab | 323,843 | 0 | 0 | 0 | For |
| Equitable | 304,452 | 0 | 0 | 0 | For |
| Royce | 244,494 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 227,245 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,700 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 61,735 | Withhold |
| State Street | 50,492 | 0 | 0 | 0 | For |
| Pacific Life | 44,764 | 0 | 0 | 0 | For |
| Invesco | 42,078 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 40,598 | Withhold |
| Bridge Builder Trust | 39,394 | 0 | 0 | 0 | For |
| Nationwide | 0 | 0 | 0 | 38,485 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 23,694 | Withhold |
| ProShares | 0 | 0 | 0 | 20,336 | Withhold |
| DWS | 0 | 0 | 0 | 18,973 | Withhold |
| Victory Capital | 0 | 0 | 0 | 15,953 | Withhold |
| Principal | 0 | 0 | 0 | 13,691 | Withhold |
| Calvert | 0 | 0 | 0 | 10,167 | Withhold |
| T. Rowe Price | 7,572 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 4,974 | 0 | Abstain |
| PENN SERIES FUNDS INC | 4,800 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.0% Majority: yes · of votes cast
Description as filed by funds: To elect three (3) nominees, David McGirr, Paula Ragan, Ph.D. and Michael Wyzga to the Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duty elected and qualified: Paula Ragan, Ph.D.
X4 PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Paula Ragan, Ph.D.”): 93,318,699 for, 928,369 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified or until their earlier death, resignation of …”
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 15,147,288 for, 4,974 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,116,249 | 0 | 0 | 0 | For |
| BlackRock | 3,598,208 | 0 | 0 | 0 | For |
| Fidelity | 2,432,292 | 0 | 0 | 0 | For |
| TIAA | 354,661 | 0 | 0 | 0 | For |
| Charles Schwab | 323,843 | 0 | 0 | 0 | For |
| Equitable | 304,452 | 0 | 0 | 0 | For |
| Royce | 244,494 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 227,245 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,700 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 61,735 | 0 | 0 | 0 | For |
| State Street | 50,492 | 0 | 0 | 0 | For |
| Pacific Life | 44,764 | 0 | 0 | 0 | For |
| Invesco | 42,078 | 0 | 0 | 0 | For |
| Voya | 40,598 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 39,394 | 0 | 0 | 0 | For |
| Nationwide | 38,485 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 23,694 | 0 | 0 | 0 | For |
| ProShares | 20,336 | 0 | 0 | 0 | For |
| DWS | 18,973 | 0 | 0 | 0 | For |
| Victory Capital | 15,953 | 0 | 0 | 0 | For |
| Principal | 13,691 | 0 | 0 | 0 | For |
| Calvert | 10,167 | 0 | 0 | 0 | For |
| T. Rowe Price | 7,572 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 4,974 | 0 | Abstain |
| PENN SERIES FUNDS INC | 4,800 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Combines 11 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: TO HOLD A NON-BINDING, ADVISORY "SAY-ON-PAY" VOTE ON THE COMPANY'S EXECUTIVE COMPENSATION.
X4 PHARMACEUTICALS INC.’s own tally for this item (“3. Non-Binding Advisory "Say-On-Pay" Vote on Named Executive Officer Compensation”): 89,159,259 for, 4,443,024 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Non-Binding Advisory "Say-On-Pay" Vote on Named Executive Officer Compensation The Company's stockholders approved, by a non-binding "say-on-pay" vote, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement relating to the An…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,116,249 | 0 | 0 | 0 | For |
| BlackRock | 3,598,208 | 0 | 0 | 0 | For |
| Fidelity | 2,432,292 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 0 | 0 | 0 | 400,000 | Withhold |
| TIAA | 354,661 | 0 | 0 | 0 | For |
| Charles Schwab | 323,843 | 0 | 0 | 0 | For |
| Equitable | 304,452 | 0 | 0 | 0 | For |
| Royce | 244,494 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 227,245 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,700 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 61,735 | 0 | 0 | 0 | For |
| State Street | 50,492 | 0 | 0 | 0 | For |
| Pacific Life | 44,764 | 0 | 0 | 0 | For |
| Invesco | 42,078 | 0 | 0 | 0 | For |
| Voya | 40,598 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 39,394 | 0 | 0 | 0 | For |
| Nationwide | 38,485 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 23,694 | 0 | 0 | 0 | For |
| ProShares | 20,336 | 0 | 0 | 0 | For |
| DWS | 18,973 | 0 | 0 | 0 | For |
| Victory Capital | 15,953 | 0 | 0 | 0 | For |
| Principal | 13,691 | 0 | 0 | 0 | For |
| Calvert | 10,167 | 0 | 0 | 0 | For |
| T. Rowe Price | 7,572 | 0 | 0 | 0 | For |
| Jackson National | 4,974 | 0 | 0 | 0 | For |
Fund voting reports, all 31 managers: 15,152,262 for, 400,000 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 14,986,793 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 14,879,809 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 7,133,515 | 0 | 0 | 0 | For |
| BlackRock | 3,593,707 | 0 | 0 | 0 | For |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 3,473,683 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,159,715 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 2,794,127 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,618,781 | 0 | 0 | 0 | For |
| State Street | 2,431,123 | 0 | 0 | 0 | For |
| UBS | 1,335,521 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 1,317,851 | 0 | 0 | 0 | For |
| Goldman Sachs | 751,606 | 0 | 0 | 0 | For |
| Northern Trust | 578,792 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 509,169 | 0 | 0 | 0 | For |
| Nuveen | 354,661 | 0 | 0 | 0 | For |
| Citadel | 350,116 | 0 | 0 | 0 | For |
| New Leaf Venture Partners, L.L.C. | 335,000 | 0 | 0 | 0 | For |
| Charles Schwab | 323,843 | 0 | 0 | 0 | For |
| Point72 | 279,359 | 0 | 0 | 0 | For |
| Knott David M Jr | 180,993 | 0 | 0 | 0 | For |
| Vanguard | 134,654 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 133,625 | 0 | 0 | 0 | For |
| AXA INVESTMENT MANAGERS UK Ltd | 0 | 124,551 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 121,022 | 0 | 0 | Against |
| Invesco | 90,727 | 0 | 0 | 0 | For |
Institutional-manager reports, all 66 managers: 62,430,907 for, 349,350 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.5% Approved · of votes cast
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
X4 PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 129,116,244 for, 620,394 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 30 asset managers below reported 15,152,262 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,116,249 | 0 | 0 | 0 | For |
| BlackRock | 3,598,208 | 0 | 0 | 0 | For |
| Fidelity | 2,432,292 | 0 | 0 | 0 | For |
| TIAA | 354,661 | 0 | 0 | 0 | For |
| Charles Schwab | 323,843 | 0 | 0 | 0 | For |
| Equitable | 304,452 | 0 | 0 | 0 | For |
| Royce | 244,494 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 227,245 | 0 | 0 | 0 | For |
| Lincoln Financial | 103,700 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 61,735 | 0 | 0 | 0 | For |
| State Street | 50,492 | 0 | 0 | 0 | For |
| Pacific Life | 44,764 | 0 | 0 | 0 | For |
| Invesco | 42,078 | 0 | 0 | 0 | For |
| Voya | 40,598 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 39,394 | 0 | 0 | 0 | For |
| Nationwide | 38,485 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 23,694 | 0 | 0 | 0 | For |
| ProShares | 20,336 | 0 | 0 | 0 | For |
| DWS | 18,973 | 0 | 0 | 0 | For |
| Victory Capital | 15,953 | 0 | 0 | 0 | For |
| Principal | 13,691 | 0 | 0 | 0 | For |
| Calvert | 10,167 | 0 | 0 | 0 | For |
| T. Rowe Price | 7,572 | 0 | 0 | 0 | For |
| Jackson National | 4,974 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 4,800 | 0 | 0 | 0 | For |
Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 167,937,781 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.24% |
| 2 | BlackRock | 2.14% |
| 3 | Fidelity | 1.45% |
| 4 | Simplify Exchange Traded Funds | 0.24% |
| 5 | TIAA | 0.21% |
| 6 | Charles Schwab | 0.19% |
| 7 | Equitable | 0.18% |
| 8 | Royce | 0.15% |
| 9 | QUANTITATIVE MASTER SERIES LLC | 0.14% |
| 10 | Lincoln Financial | 0.06% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | NEA Management Company, LLC | 8.92% |
| 2 | Bain Capital Life Sciences Investors, LLC | 8.86% |
| 3 | ORBIMED ADVISORS LLC | 4.25% |
| 4 | BlackRock | 2.14% |
| 5 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 2.07% |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.88% |
| 7 | Soleus Capital Management, L.P. | 1.66% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.56% |
| 9 | State Street | 1.45% |
| 10 | UBS | 0.80% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Acorn | 10.63% | DEF14A |
| Entities affiliated with Growth Equity Opportunities 18 VGE, LLC | 10.12% | DEF14A |
| Entities affiliated with Bain Capital Life Sciences Investors, LLC | 10.12% | DEF14A |
| Entities affiliated with OrbiMed | 6.84% | DEF14A |
| The Vanguard Group | 4.88% | 13G |
| Geode Capital | 1.75% | 13F |
| State Street | 1.50% | 13F |
| Paula Ragan, Ph.D. | 0.65% | DEF14A |
| Northern Trust | 0.63% | 13F |
| Citadel Advisors | 0.53% | 13F |
Percentages above are of 167,937,781 shares outstanding, as reported by X4 PHARMACEUTICALS INC. on its Form 10-Q dated May 3, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from X4 PHARMACEUTICALS INC.’s 10-Q dated May 3, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
X4 PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “X4 PHARMACEUTICALS (XFOR) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/x4-pharmaceuticals-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.